Meridian Intelligence · Global Finance Intelligence

6 hr ago

STXS

Stereotaxis expects recurring revenue to reach $8M in Q4 2026 as MAGiC adoption remains supply constrained

Stereotaxis expects recurring revenue to reach $8M in Q4 2026 as MAGiC adoption remains supply constrained. Market participants are assessing the implications f…

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Healthcare

Stereotaxis expects recurring revenue to reach $8M in Q4 2026 as MAGiC adoption remains supply constrained

Allogene Therapeutics Q2 2026 Earnings Preview

Omeros Q2 2026 Earnings Preview

Fortress Biotech Q2 Earnings Preview

Talphera Q2 2026 Earnings Preview

MariMed Q2 Earnings Preview

Atea Pharmaceuticals Q2 2026 Earnings Preview

OptimizeRx Q2 2026 Earnings Preview

Kura Oncology Q2 2026 Earnings Preview

STAAR Surgical Q2 2026 Earnings Preview

Inovio Pharmaceuticals Q2 2026 Earnings Preview

Eupraxia Pharmaceuticals reports Q2 results

Alcon targets 12%-15% core EPS growth in 2026 as it plans to reinvest $60M tariff refund

Microbot Medical GAAP EPS of -$0.08 in-line, revenue of $0.24M misses by $0.16M

BrainsWay Q2 2026 Earnings Preview

Liquidia Q2 2026 Earnings Preview

Achieve Life Sciences GAAP EPS of -$0.80 misses by $0.64

Mereo BioPharma Group GAAP EPS of -$0.01 in-line

Theriva Biologics GAAP EPS of -$0.07 misses by $0.01

Imunon GAAP EPS of -$0.54 beats by $0.50

Aura Biosciences GAAP EPS of -$0.48 misses by $0.10

Upstream Bio, Inc. reports Q2 results

Fennec Pharmaceuticals GAAP EPS of $0.05 beats by $0.04, revenue of $17.87M beats by $1.75M

Harvard Bioscience beats top-line and bottom-line estimates; gives Q3 and raises FY2026 outlook

Xtant Medical misses top-line and bottom-line estimates; lowers FY2026 outlook

Legend Biotech Non-GAAP EPS of $0.16 misses by $0.12, revenue of $387.5M beats by $35.75M

Autolus Therapeutics GAAP EPS of -$0.15 beats by $0.04, revenue of $45.69M beats by $5.54M

Earnings Snapshot: Cardinal Health issues FY27 Non-GAAP EPS outlook above long-term target

Cardinal Health declares $0.5158 dividend

Healthcare

Stereotaxis expects recurring revenue to reach $8M in Q4 2026 as MAGiC adoption remains supply constrained

Allogene Therapeutics Q2 2026 Earnings Preview

Omeros Q2 2026 Earnings Preview

Fortress Biotech Q2 Earnings Preview

Talphera Q2 2026 Earnings Preview

MariMed Q2 Earnings Preview

Atea Pharmaceuticals Q2 2026 Earnings Preview

OptimizeRx Q2 2026 Earnings Preview

Kura Oncology Q2 2026 Earnings Preview

STAAR Surgical Q2 2026 Earnings Preview

Inovio Pharmaceuticals Q2 2026 Earnings Preview

Eupraxia Pharmaceuticals reports Q2 results

Alcon targets 12%-15% core EPS growth in 2026 as it plans to reinvest $60M tariff refund

Microbot Medical GAAP EPS of -$0.08 in-line, revenue of $0.24M misses by $0.16M

BrainsWay Q2 2026 Earnings Preview

Liquidia Q2 2026 Earnings Preview

Achieve Life Sciences GAAP EPS of -$0.80 misses by $0.64

Mereo BioPharma Group GAAP EPS of -$0.01 in-line

Theriva Biologics GAAP EPS of -$0.07 misses by $0.01

Imunon GAAP EPS of -$0.54 beats by $0.50

Aura Biosciences GAAP EPS of -$0.48 misses by $0.10

Upstream Bio, Inc. reports Q2 results

Fennec Pharmaceuticals GAAP EPS of $0.05 beats by $0.04, revenue of $17.87M beats by $1.75M

Harvard Bioscience beats top-line and bottom-line estimates; gives Q3 and raises FY2026 outlook

Xtant Medical misses top-line and bottom-line estimates; lowers FY2026 outlook

Legend Biotech Non-GAAP EPS of $0.16 misses by $0.12, revenue of $387.5M beats by $35.75M

Autolus Therapeutics GAAP EPS of -$0.15 beats by $0.04, revenue of $45.69M beats by $5.54M

Earnings Snapshot: Cardinal Health issues FY27 Non-GAAP EPS outlook above long-term target

Cardinal Health declares $0.5158 dividend